棕榈酸帕利哌酮注射液与帕利哌酮缓释片对精神分裂症患者疗效和安全性的比较

发布时间：2018-06-30 10:55

本文选题：精神分裂症 + 棕榈酸帕利哌酮注射液　；参考：《广东医学》2014年09期

【摘要】：目的比较两种不同剂型帕利哌酮(棕榈酸帕利哌酮注射液与口服帕利哌酮缓释片)对精神分裂症患者疗效、安全性、社会功能和用药满意度的影响。方法 80例口服帕利哌酮缓释片3~12 mg/d达6周且病情稳定的精神分裂症患者,被随机分为注射组和口服组。口服组根据病情维持帕利哌酮缓释片剂量3~12 mg/d;注射组根据病情采用棕榈酸帕利哌酮"起始治疗模式",分组日开始注射棕榈酸帕利哌酮注射液150 mg,第8天后注射100 mg,第5周根据病情和患者自身情况注射75~150 mg。于分组前及分组后5、9和13周评估阳性和阴性症状量表(PANSS)、不良反应量表(TESS)以评定疗效和不良反应,评估社会功能量表(PSP)以评定患者的社会功能,评估用药满意度问卷(MSQ)以评定患者用药主观感受。结果注射组40例患者中,有37例(92.5%)完成研究,口服组40例患者中,有32例(80%)完成研究,将完成全部研究的患者的资料纳入统计分析。分组前两组的PNASS、TESS、PSP和MSQ评分比较差异均无统计学意义。分组治疗5、9和13周后,两组PANSS、TESS评分较分组前均有改善,但注射组与口服组两组间比较差异无统计学意义;分组治疗5、9和13周后,注射组和口服组的PSP、MSQ评分均明显提高,且两组间比较差异均有统计学意义(P0.005)。结论棕榈酸帕利哌酮注射液与口服帕利哌酮缓释片疗效和安全性相当,但在社会功能恢复和患者用药满意度方面存在优势。
[Abstract]:Objective to compare the efficacy, safety, social function and drug satisfaction of two different formulations of palipioperazone palmitate injection and oral parperoperazone sustained-release tablets in patients with schizophrenia. Methods Eighty schizophrenic patients with stable state of condition who had been treated with Pariperidone sustained-release tablets for 6 weeks were randomly divided into two groups: the injection group and the oral group. The oral group maintained the sustained release tablet of Paripiperone at a dose of 3 ~ 12 mg / d, and the injection group was given a "starting treatment model" of palipiperone palmitate according to the condition of the disease. The injection of palipioperazone palmianate injection began at 150 mg on the day of grouping and was injected into 100 mg after 8 days. MG, 75 mg, 150 mg, according to the patient's condition and the patient's condition in the fifth week. The positive and negative symptom scale (PANSS), adverse reaction scale (Tess) and social function scale (PSP) were evaluated before and 5 and 13 weeks after the grouping. Drug satisfaction questionnaire (MSQ) was used to assess the subjective feeling of drug use. Results of the 40 patients in the injection group, 37 (92.5%) completed the study, 32 (80%) of the 40 patients in the oral group completed the study, and the data of the patients who completed all the studies were included in the statistical analysis. There was no significant difference in PNASS and MSQ scores between the two groups. After 5 weeks and 13 weeks of treatment, the scores of PANSSTSS were improved in both groups, but there was no significant difference between the injection group and the oral group, and the PSPN MSQ scores of the injection group and the oral group were significantly increased after 5 weeks and 13 weeks of treatment. The difference between the two groups was statistically significant (P 0.005). Conclusion Paripiperone palmitate injection has the same efficacy and safety as that of oral parpipraxone sustained-release tablets, but it has advantages in social function recovery and patients' satisfaction with drug use.
【作者单位】：广东省佛山市第三人民医院临床心理科;
【分类号】：R749.3

【共引文献】